Beitrag aus dem Handbuch "Biologische Gefahren II - Entscheidungshilfen zu medizinisch angemessenen Vorgehensweisen in einer B-Gefahrenlage".
Das Kompendium setzt sich mit der medizinischen Versorgung von Personen auseinander, die biowaffenfähigen Erregern vermutlich oder gesichert ausgesetzt war...en. Es richtet sich in erster Linie an Ärzte, sonstiges medizinisches Personal, Hilfsorganisationen und Personen aus öffentlichen Einrichtungen sowie an die Bevölkerung, die aus beruflichen oder privaten Gründen an dem Thema interessiert ist.
more
Eine wachsende Anzahl von Studierenden interessiert sich für Global Health. Bisher mangelt es jedoch an ausreichenden Angeboten zur Verwirklichung von studentischen Global-Health-Forschungsprojekten. Um vor diesem Hintergrund interessierte Studierende auf ihrem Weg zum eigenen Global-Health-Forschu...ngsprojekt zu unterstützen, hat die AG Forschungsplattform der Global Health Alliance-Deutschland (GHA-D), in Kooperation mit weiteren Institutionen, das Handbuch "Forschung mit Weitblick" entwickelt. Neben Hintergrundinformationen und Anregungen zur kritischen Reflexion werden in dem Handbuch eine Auswahl von Forschungsarbeiten mit Global-Health-Bezug sowie erste Schritte zur Umsetzung eines eigenen Forschungsprojekts vorgestellt.
more
Evaluation of the effectiveness of vaccines against COVID-19
INTERIM GUIDANCE 17 MARCH 2021
The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the... disease, as well as to minimize the risks (of exacerbations, disease instability, accelerated loss of lung function, and adverse treatment effects). That requires an approach that is personalized in terms of the pharmacological treatment, patient education, written action plan, training in correct inhaler use, and review of the inhaler technique at each office visit. A panel of 22 pulmonologists was invited to perform a critical review of recent evidence of pharmacological treatment of asthma and to prepare this set of recommendations, a treatment guide tailored to use in Brazil. The topics or questions related to the most significant changes in concepts, and consequently in the management of asthma in clinical practice, were chosen by a panel of experts. To formulate these recommendations, we asked each expert to perform a critical review of a topic or to respond to a question, on the basis of evidence in the literature. In a second phase, three experts discussed and structured all texts submitted by the others. That was followed by a third phase, in which all of the experts reviewed and discussed each recommendation. These recommendations, which are intended for physicians involved in the treatment of asthma, apply to asthma patients of all ages.
more
This document outlines the working structure and guiding principles for collaboration of COVAX, the Vaccines pillar of the Access to COVID-19 Tools Accelerator (ACT-A). The working structure of COVAX continues to adapt to emerging needs and the changing trajectory of the pandemic. Some components of... the pandemic response capabilities united under COVAX may eventually be integrated into regional, national and sub national health systems, routine immunization programmes and future global pandemic preparedness and response (PPR) structures. Therefore, the working structures outlined in this document continue to evolve and the document provides a snapshot of the COVAX ways of working in the first half of 2022.
more
Interim guidance, 6 October 2021
Direct detection of SARS-CoV-2 viral proteins (antigens) in nasal swabs and other respiratory secretions using lateral flow immunoassays (also known as rapid diagnostic tests, RDTs) offers a faster and less expensive method to test for SARS-CoV-2 than the reference ...method, nucleic acid amplification tests (NAATs). This interim guidance offers recommendations on the priority uses of antigen-detecting rapid diagnostic tests (Ag-RDTs) in specific populations and settings, including (i) for primary case detection in symptomatic individuals suspected to be infected and asymptomatic individuals at high risk of COVID-19, (ii) for contact tracing, (iii) during outbreak investigations and (iv) to monitor trends of disease incidence in communities. Ag-RDTs meeting minimum performance requirements can be used outside of clinical and laboratory settings, including in communities, by trained operators in accordance with instructions. The guidance additionally provides recommendations on implementation, product selection and storage.
more
Orientação provisória, 6 de abril de 2020
Este documento resume as recomendações da OMS para o uso racional de equipamentos de proteção individual (EPIs) em unidades de saúde e na assistência domiciliar, bem como no manuseio de cargas; avalia também a situação atual da cadeia de abastec...imento global e as considerações para tomada de decisão durante desabastecimentos graves de EPIs.Este documento não inclui recomendações para membros da comunidade em geral. Clique aqui para mais informações sobre recomendações da OMS para uso de máscara na comunidade em geral.Nesse contexto, EPIs incluem luvas, máscaras faciais cirúrgicas/de uso médico - aqui denominadas “máscaras cirúrgicas”, óculos de proteção, protetor facial do tipo face shield, e aventais, bem como itens para procedimentos específicos - respiradores com máscara facial de filtração (padrão N95 ou PFF2 ou PFF3 ou equivalente) - aqui denominados “respiradores” - e capotes
more
Orientations provisoires
6 avril 2020
Le présent document résume les recommandations de l’OMS sur l’utilisation rationnelle de l’équipement de protection individuelle (EPI) dans les établissements de santé et lors des soins à domicile, ainsi que lors de la manipulation des cargaison...s; il évalue également les perturbations qui touchent actuellement la chaîne d’approvisionnement mondiale et les éléments à considérer pour la prise de décisions en cas de grave pénurie d’EPI.
more
Washington, D.C., EUA, del 23 al 27 de septiembre del 2018
Punto 8.22 del orden del día provisional
CD56/INF/22 31 de agosto del 2018
Original: inglés/español